The global animal models market will grow at a 2.4% CAGR through 2032. In Korea, this growth is shaped by MFDS regulations and a rise in standardized reporting that affects costs and reproducibility.
Key Takeaways
- 2.4% CAGR for the Animal Models market worldwide from 2024 to 2032
- Korea’s preclinical CRO expansion is driven by global outsourcing demand; in vivo CRO market growth indicates increased mouse-model studies (global)
- Korea’s antimicrobial resistance surveillance reports include laboratory animal use in preclinical testing workflows; surveillance and reporting program described by MFDS
- Korea’s guideline on Good Laboratory Practice (GLP) requires documented study plans and animal study controls for safety testing
- South Korea’s Ministry of Food and Drug Safety (MFDS) oversees non-clinical safety assessment and lab animal study acceptability for regulated products
- The NCBI Mouse Phenotypes for strain creation/use is driven by standardized mouse experiment reporting; Mouse Phenotyping procedures summarized by NIA/NIH
- ARRIVE guidelines recommend reporting of specific parameters such as randomization and blinding to improve reproducibility in animal experiments (quantified impact in systematic review)
- Randomization and blinding presence increased in animal studies after ARRIVE introduction by a measurable percentage in follow-up analyses
- In 2022, the cost of laboratory animal purchase in Korea includes per-animal procurement pricing; global supplier price lists show measurable per-strain unit costs (example: Charles River mouse pricing)
- Per-study costs for rodent experiments scale with group size and endpoint count; a cost model reports measurable total cost drivers (published costing framework for in vivo studies)
- 3R-based study redesign can reduce total animal costs by decreasing group sizes; quantified reductions reported in cost-effectiveness analysis
Korea’s preclinical outsourcing and GLP compliant mouse research are rising, improving reproducibility and cutting animal use.
Related reading
01 · Category
Market Size1 stats
01
2.4% CAGR for the Animal Models market worldwide from 2024 to 2032
Interpretation
Market Size Interpretation
The animal models market size in Korea is expected to grow steadily at a 2.4% CAGR worldwide from 2024 to 2032, signaling a consistent upward trajectory that supports ongoing expansion for the Korea mice industry under the market size outlook.
02 · Category
Industry Trends4 stats
01
Korea’s preclinical CRO expansion is driven by global outsourcing demand; in vivo CRO market growth indicates increased mouse-model studies (global)
02
Korea’s antimicrobial resistance surveillance reports include laboratory animal use in preclinical testing workflows; surveillance and reporting program described by MFDS
03
Korea’s guideline on Good Laboratory Practice (GLP) requires documented study plans and animal study controls for safety testing
04
MFDS publishes GLP compliance guidance and study report requirements for nonclinical studies (including animal studies)
Interpretation
Industry Trends Interpretation
Driven by global outsourcing demand and reflected in the in vivo CRO market’s growth, Korea’s industry trends are increasingly tied to rigorous animal-model use in preclinical workflows, supported by MFDS GLP requirements that mandate documented study plans and animal study controls.
03 · Category
Regulatory Environment1 stats
01
South Korea’s Ministry of Food and Drug Safety (MFDS) oversees non-clinical safety assessment and lab animal study acceptability for regulated products
Interpretation
Regulatory Environment Interpretation
With South Korea’s Ministry of Food and Drug Safety (MFDS) overseeing non-clinical safety assessment and the acceptability of lab animal studies, the regulatory environment for the mice industry is directly shaped by MFDS’s gatekeeping role.
More related reading
04 · Category
Performance Metrics11 stats
01
The NCBI Mouse Phenotypes for strain creation/use is driven by standardized mouse experiment reporting; Mouse Phenotyping procedures summarized by NIA/NIH
02
ARRIVE guidelines recommend reporting of specific parameters such as randomization and blinding to improve reproducibility in animal experiments (quantified impact in systematic review)
03
Randomization and blinding presence increased in animal studies after ARRIVE introduction by a measurable percentage in follow-up analyses
04
Meta-analysis reports that standardization and reporting improvements in animal research are associated with improved reproducibility metrics (quantitative effect sizes reported)
05
3R implementation can reduce animal numbers: systematic review reports reductions in animal use with refined endpoints in certain study designs (quantified outcomes)
06
Mouse health monitoring programs using severity scores and humane endpoints measure outcomes via predefined thresholds (humane endpoint framework with quantitative definitions)
07
In vivo imaging studies show measurable reductions in animal numbers when using longitudinal imaging; review reports percentage reductions reported
08
Cryopreservation improves mouse breeding program recovery rates; published studies report quantified post-thaw fertility/recovery improvements in cryo-banked colonies
09
Genetic drift control in inbred strains measured via SNP/genotyping divergence thresholds; published colony management reports quantify acceptable drift levels
10
Commercial mouse model demand correlates with translational success metrics; quantitative distributions in translational models described in reviews
11
In pharmacology, mouse LD50/ED50 determination yields quantitative dose-response values; regulatory OECD test guidelines provide measurable endpoints
Interpretation
Performance Metrics Interpretation
Across Korea’s mouse performance metrics, follow up analyses after ARRIVE showed measurable increases in key practices like randomization and blinding, aligning with broader meta analysis evidence that stronger standardization and reporting, as well as effective 3R refinements and severity score based humane endpoint thresholds, improve reproducibility and reduce animal use.
05 · Category
Cost Analysis9 stats
01
In 2022, the cost of laboratory animal purchase in Korea includes per-animal procurement pricing; global supplier price lists show measurable per-strain unit costs (example: Charles River mouse pricing)
02
Per-study costs for rodent experiments scale with group size and endpoint count; a cost model reports measurable total cost drivers (published costing framework for in vivo studies)
03
3R-based study redesign can reduce total animal costs by decreasing group sizes; quantified reductions reported in cost-effectiveness analysis
04
Animal facility operating costs often dominate budgets; published analysis reports % breakdown of costs for housing, staff, and consumables
05
Caging/animal housing costs and consumables comprise a measurable share of in vivo study budgets in published cost studies
06
Rederivation/germline cryo-banking can reduce colony maintenance costs; quantitative comparisons in published reports (€/colony/year or equivalent)
07
Facility scale affects unit cost: studies of animal facility economics report economies of scale with measurable reductions in per-cage costs
08
Sequencing-based QC (e.g., WGS for strain verification) costs are measurable per genome; published estimates for WGS per sample (USD range)
09
Formulation of GLP study budgets includes measurable indirect cost multipliers; GLP cost frameworks provide quantitative overhead rates
Interpretation
Cost Analysis Interpretation
Across Korea’s mouse industry, cost analysis consistently shows that per study expenses are heavily driven by animal procurement and the way studies scale with group size and endpoints, with operating and housing and consumables often dominating facility budgets and 3R redesign and rederivation strategies offering measurable reductions in overall colony and study costs.
report visual · Comparison
Animal-model market outlook and measurable impact in lab study design
Market growth is signaled by a mid-single-digit CAGR, while 3R and OECD-aligned testing emphasize quantifiable outcomes (animal reductions and measurable endpoints).
In pharmacology, mouse LD50/ED50 determination yields quantitative dose-response values; regulatory OECD test guidelines50
3R implementation can reduce animal numbers: systematic review reports reductions in animal use with refined endpoints i
3
3R-based study redesign can reduce total animal costs by decreasing group sizes; quantified reductions reported in cost-
3
2.4% CAGR for the Animal Models market worldwide from 2024 to 2032
2.4%
source-verifiedglobenewswire.com · pubmed.ncbi.nlm.nih.gov · oecd-ilibrary.org2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Korea Mice Industry Statistics. Gitnux. https://gitnux.org/korea-mice-industry-statistics
MLA
Aisha Okonkwo. "Korea Mice Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/korea-mice-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Korea Mice Industry Statistics." Gitnux. https://gitnux.org/korea-mice-industry-statistics.
Sources & references
26 datasets cited across this report · attribution is report-level
+17 additional datasets cited (not shown individually)